Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

History

Oyster Point was founded in 2014 by two industry veterans with decades of experience in the biopharmaceutical space. Oyster Point has since grown to become a leader in the field of biotechnology, developing innovative treatments and diagnostics across multiple therapeutic areas.

Mission

Our mission is to develop and commercialize innovative treatments and diagnostics that bring substantial medical value to the healthcare system.

Vision

To create a healthier world by unlocking the full potential of new technologies and therapies to liberate people from chronic inflammatory diseases.

Key Team

Dr. Eric Carlson Ph.D. (Chief Scientific Officer)

Mr. Barry Rosenfeld J.D. (Sr. VP & Gen. Counsel)

Ms. Raegan A. McClain CCEP, J.D., L.L.M. (Chief Compliance & Privacy Officer)

Arty Ahmed (VP of Investor relations)

Ms. Karen Castillo-Paff (VP of Communications & PR)

Mr. Dave Benadon (Chief HR Officer)

Ms. Loni Da Silva M.S. (Sr. VP of Regulatory Affairs)

Recognition and Awards

Oyster Point has won numerous awards for its work, including the Wallace H. Coulter Award for Excellence in Innovation, the Society for Clinical Investigation’s Young Investigator Award, and the Association of Biomolecular Resource Facilities’ Open Science Award.